Sacrix

Sacrix LLC, FDA approved since 2015, has been transforming sacroiliac (SI) joint fusion with its LESS™ Exposure Spine Surgery technology, pioneering the 100% fluoroscopic percutaneous posterior lateral-oblique SI joint fusion technique. Wholly owned by NANISX (a KIC Ventures portfolio company), Sacrix has patented titanium triangular implant (TTI) screw technologies designed for outpatient SI joint stabilization. Guided by the LESS™ REP principles - Restore Function, Early Intervention, and Preserve Anatomy, Sacrix provides an efficient and reproducible solution for patients suffering from SI joint dysfunction and lower back pain. By shifting procedures from hospitals to outpatient centers, Sacrix enables interventional pain doctors and spine surgeons to perform faster, safer, and more effective SI joint fusions. With proven clinical outcomes, growing adoption, and expanding reimbursement coverage, Sacrix is driving the evolution of SI joint care in ambulatory surgery centers (ASCs) and office-based labs (OBLs).

• Employees 2